Safety of topical administration of nasal decongestants and vasoconstrictors in paediatric nasal surgery – A systematic review

MacMillan, Andrew; Phoon, Kar; Edafe, Ovie

doi:10.1016/j.ijporl.2021.111010

Cited by 2 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Oxymetazoline hydrochloride (the molecular mass, 296.84) 33 is a synthetic sympathomimetic agonist with a high affinity for α 1A ‐adrenergic receptors and a partial affinity for α 2A ‐adrenergic receptors. Activation of these postsynaptic adrenoceptors promotes superficial cutaneous vasoconstriction 34–36 . Furthermore, preclinical models also suggested that adrenoceptor agonists might have anti‐inflammatory effects by reducing the production of proinflammatory cytokines and antineovascularization effects by reducing vascular endothelial growth factors 19–22 .…”

Section: Discussionmentioning

confidence: 99%

“…Activation of these postsynaptic adrenoceptors promotes superficial cutaneous vasoconstriction. [34][35][36] Furthermore, preclinical models also suggested that adrenoceptor agonists might have anti-inflammatory effects by reducing the production of proinflammatory cytokines and antineovascularization effects by reducing vascular endothelial growth factors. [19][20][21][22] We hypothesized that OxH improved PAE through its vasoconstrictive, anti-inflammatory, and antineovascularization properties.…”

Section: Safety Assessmentmentioning

confidence: 99%

See 1 more Smart Citation

The role of the topical nasal decongestant oxymetazoline as a novel therapeutic option for post‐acne erythema: A split‐face, double‐blind, randomized, placebo‐controlled trial

Washrawirul

Puaratanaarunkon

Chongpison

et al. 2023

The Journal of Dermatology

View full text Add to dashboard Cite

Post-acne erythema (PAE) is one of the most common sequelae of acne inflammation.Unfortunately, the treatment of PAE remains challenging due to limited effective topical treatments. The objectives of this study were to evaluate the efficacy and safety of topical oxymetazoline hydrochloride (OxH) 0.05% solution for PAE. This study was a splitface, participants-and investigators-blinded, randomized, placebo-controlled trial conducted between December 2021 and March 2022 in Bangkok, Thailand. Healthy adults aged from 18 to 45 years with mild to severe PAE, according to the Clinician's Erythema Assessment (CEA), on both sides of the face were eligible. After randomization, each participant applied the OxH to one side of their face and a placebo to the contralateral face twice daily for 12 weeks. The primary outcome was PAE lesion counts. The secondary outcomes were erythema index, clinical response rate at week 12 ("clear," "almost clear,"or "at least two-grade improvement" by CEA), and patient satisfaction scores. A total of 30 participants were enrolled. The OxH-treated skin showed a significantly greater mean difference (MD) reduction in PAE lesion counts than the placebo after 8 weeks of treatment (4.30, 95% confidence interval [CI] 1.42-7.18). Similarly, the MD reduction of the erythema index was higher in the OxH-treated skin from the second week (11.82,. Additionally, the OxH-treated side also achieved a higher clinical response rate after 8 weeks of treatment (40.00% vs. 6.67%; p = 0.002) and rated higher satisfaction than those using the placebo at the end of the study (mean [standard deviation] satisfaction score 8.30 [0.18] vs 7.40 [0.18], P < 0.001). There were no serious adverse events or flares of erythema during the study. In conclusion, our study demonstrated that the topical OxH 0.05% solution was effective, well-tolerated, and safe for reducing PAE without a rebound effect. It could be a choice of PAE management. Trial Registration: Thai Clinical Trials Registry No. TCTR20211207004.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Safety Assessmentmentioning

confidence: 99%

The role of the topical nasal decongestant oxymetazoline as a novel therapeutic option for post‐acne erythema: A split‐face, double‐blind, randomized, placebo‐controlled trial

Washrawirul

Puaratanaarunkon

Chongpison

et al. 2023

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…Вони стимулюють альфа-адренергічні рецептори в кровоносних судинах слизової оболонки носа, викликаючи звуження судин. Це звужує набряклі носові ходи та полегшує дихання [6,18,19,22,30].…”

Section: вступunclassified

Comparative review of the preclinical safety of topical decongestants xylometazoline and oxymetazoline

Hrytsun,

Grebeniuk,

Nikulchenko

et al. 2023

Rep. of Vinnytsia Nation. Med. Univ.

View full text Add to dashboard Cite

Annotation. Xylometazoline and oxymetazoline are two commonly used nasal decongestants that provide temporary relief from nasal congestion caused by colds, allergies, and sinusitis. The mechanism of action of both drugs consists in the narrowing of blood vessels in the nasal passages, reducing oedema, rhinorrhoea and congestion. The aim of the study was to analyse literature data and assess the preclinical safety of xylometazoline and oxymetazoline. 32 scientific sources were selected and reviewed from the Scopus, Web of science, PubMed, and ScienceDirect databases. In the process of processing the search results, either the most recent publications (for the last 10 years) or the latest publications on this issue (regardless of the age) were selected. Our analysis of scientific literature data allows us to state that neither xylometazoline nor oxymetazoline show any effects in animals that would have possible toxicological significance for patients. Since the doses used in experimental studies on animals were quite high and administered over a long period of time to determine possible adverse events, it can be concluded that there are no preclinical reasons to consider these drugs dangerous for human use at the recommended doses and indications.

show abstract

Safety of topical administration of nasal decongestants and vasoconstrictors in paediatric nasal surgery – A systematic review

Cited by 2 publications

References 27 publications

The role of the topical nasal decongestant oxymetazoline as a novel therapeutic option for post‐acne erythema: A split‐face, double‐blind, randomized, placebo‐controlled trial

The role of the topical nasal decongestant oxymetazoline as a novel therapeutic option for post‐acne erythema: A split‐face, double‐blind, randomized, placebo‐controlled trial

Comparative review of the preclinical safety of topical decongestants xylometazoline and oxymetazoline

Contact Info

Product

Resources

About